News & Events about Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT Get Rating) COO Azmi Nabulsi acquired 10,000 shares of the businesss stock in a transaction that occurred on Tuesday, April 11th. The stock was bought at an average cost of $8.26 per share, for a total transaction of $82,600.00. Following the...
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT Get Rating) COO Azmi Nabulsi acquired 10,000 shares of the businesss stock in a transaction that occurred on Tuesday, April 11th. The stock was bought at an average cost of $8.26 per share, for a total transaction of $82,600.00. Following the completion of ...
FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the ...
Needham & Company LLC restated their buy rating on shares of Phathom Pharmaceuticals (NASDAQ:PHAT Get Rating) in a report published on Wednesday, Benzinga reports. The brokerage currently has a $23.00 price objective on the stock. A number of other research analysts have also weighed in on PHAT. ...
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT...